CoChat

Vortioxetine: a novel antidepressant for the treatment of major depressive disorder

Gonda, Xenia, Sharma, Samata R., Tarazi, Frank I. · 2019 · Expert Opinion on Drug Discovery

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5–20 mg. The recommended starting dose is 10 mg administered orally once daily without the need for food.Areas covered: This review focuses on the preclinical and clinical discovery of vortioxetine. It analyzes the pharmacological, neurochemical, and behavioral mechanisms of the medication and how these contribute to its potential therapeutic advantages as described in published preclinical and clinical studies and product labels.Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Functional studies show that vortioxetine acts as a SERT blocker, a 5-HT3, 5-HT7 receptor antagonist, and a 5-HT1A receptor agonist. The drug is active in animal models predictive of antipsychotic and antidepressant activities and demonstrates procognitive effects in several animal models that assessed memory, cognition, and executive functions. Short- and long-term clinical trials demonstrated the clinical efficacy of vortioxetine in treating depressive symptoms and cognitive deficits in MDD patients. It also displays fairly benign safety and tolerability profiles. Vortioxetine’s unique psychopharmacological properties might contribute to an improved clinical outcome in MDD patient populations.

Overview

Integrity signals

Registry

Crossref · 10.1080/17460441.2019.1546691

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 86 · Cited by 123

Research works printed but not linked: 4

  1. Nierenberg AA., 2001, Am J Manag Care, 7, S353
  2. Westrich L, 2012, Int J Psychiatry Clin Pract, 16, 47
  3. 10.1124/pr.59.07103 · doi:10.1124/pr.59.07103 · Paper page
  4. Stuchilk A, 2014, Fron Behav Neurosci, 8

Metadata

Authors
Gonda, X., Sharma, S. R., & Tarazi, F. I.
Affiliations
  • Department of Psychiatry and Psychotherapy, Kutvolgyi Clinical Centre, Semmelweis University, Budapest, Hungary
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
Corresponding author
Tarazi, Frank I.
Venue
Expert Opinion on Drug Discovery
Published
2018-11-20
Volume
14
Issue
1
Pages
81-89
ISSN
  • 1746-0441 (ISSN-L)
  • 1746-045X
OpenAlex
W2901835156
Cited by
123
References
86
Citations by year
2026: 7 · 2025: 21 · 2024: 15 · 2023: 18 · 2022: 30 · 2021: 17 · 2020: 10 · 2019: 5
FWCI
5.16
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
  • Semmelweis University Repository (Semmelweis University) (submittedVersion)
Funders
Janos Bolyai Research Fellowship
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
vortioxetine, major depressive disorder, antidepressants, serotonin transporter, 5-HT3 receptor antagonists, 5-HT1A receptor agonist, 5-HT7 receptor, cognitive enhancement, memory, executive function, drug discovery, safety and tolerability
MeSH terms
Vortioxetine, Animals, Antidepressive Agents, Major Depressive Disorder, Drug Evaluation, Preclinical, Humans, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. https://app.cochat.ai/papers/10.1080/17460441.2019.1546691
The paper
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019). Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2019.1546691

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.